PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9900
-0.0500 (-4.81%)
As of 2:48PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0200
Bid0.99 x 800
Ask1.00 x 1100
Day's Range0.9800 - 1.0335
52 Week Range0.9800 - 1.6500
Volume302,605
Avg. Volume218,468
Market Cap114.643M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has entered into a license agreement with a subsidiary of Chart Industries, Inc. regarding Pluristem’s thawing device for cell-based therapies. Pluristem’s point-of-care thawing device technology is designed to allow for the precise and automated thawing of cells in a controlled and monitored environment, and is expected to result in the highest levels of cell viability and quality. The technology includes many advanced unique proprietary features which were designed to result in the leading thawing devices on the market.

  • GlobeNewswire7 days ago

    Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented data from the first cohort of patients in its ongoing Phase I clinical trial of PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT) at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, which is being held December 1-4 in San Diego.

  • Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks10 days ago

    Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

    Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswire12 days ago

    Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematology’s (ASH) Annual Meeting

    A Phase I study of PLX-R18 cells to treat incomplete hematopoietic recovery following HCT is ongoing in U.S. and Israel. The trial is designed as a multi-center, open-label, dose-escalating study to evaluate the safety of intramuscular injections (IM) of PLX-R18 cells in 24 subjects with incomplete hematopoietic recovery persisting for at least 4 months after HCT.

  • What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)?
    Simply Wall St.20 days ago

    What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc (NASDAQ:PSTI)?

    The big shareholder groups in Pluristem Therapeutics Inc (NASDAQ:PSTI) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...

  • GlobeNewswire21 days ago

    Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire28 days ago

    New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) at the 2018 American Heart Association Scientific Sessions in Chicago. The data were presented by Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead European Principal Investigator for the Phase II IC study.

  • Associated Presslast month

    Pluristem: Fiscal 1Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $4,000 in the period. The company's shares closed at $1.18. A year ago, they were trading ...

  • GlobeNewswirelast month

    Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended September 30, 2018 and provided a corporate update. “We were very pleased to announce this quarter on FDA approval of an expanded access program that will provide critical limb ischemia patients who are not suitable for enrollment in our Phase III trial with access to PLX-PAD while the trial is ongoing,” said Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “During the fiscal first quarter and subsequent period, we continued to make progress advancing our pipeline of novel placenta-based cell therapy products in multiple indications.” Mr. Yanay continued, "We are making good progress in enrolling patients in both ongoing Phase III clinical trials of PLX-PAD in critical limb ischemia (CLI) and the treatment of muscle injury following hip fracture.

  • GlobeNewswire2 months ago

    Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company will be presenting at four conferences during November: at the BioEurope conference, which is being held November 5–7, 2018 in Copenhagen, at the 15th Annual Vascular Interventional Advances (VIVA) Conference, which is being held November 5-8 in Las Vegas, at the 2018 American Heart Association (AHA) Scientific Sessions, which are being held November 10-12 in Chicago and the Cell and Gene Therapy Manufacturing conference, which is being held November 14-15 in London. At the AHA Scientific Sessions, Prof. Norbert Wiess, the Principal Investigator of the Company’s Phase II intermittent claudication (IC) study, will present detailed results from the study.

  • GlobeNewswire2 months ago

    U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial Inc., a privately-held third-party sponsor of authorized Expanded Access Programs (EAPs), today announced that the parties have entered into agreement to initiate an FDA-cleared EAP for Pluristem’s cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI). The parties further announced that the FDA has authorized WideTrial to charge payment for the PLX-PAD EAP treatment.

  • What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?
    Simply Wall St.3 months ago

    What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?

    Pluristem Therapeutics Inc (NASDAQ:PSTI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PSTIRead More...

  • Benzinga4 months ago

    Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

    With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst  George ...

  • ACCESSWIRE5 months ago

    Free Technical Reports on Portola Pharma and Three Additional Biotech Equities

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.6 months ago

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...